Light and sound therapy for newly diagnosed glioblastoma
Part of Cancer clinical trials.
This trial tests a new approach that uses a light-sensitive drug and low-intensity ultrasound to make standard chemotherapy more effective for glioblastoma. If you have completed initial treatment with radiation and temozolomide without the tumor growing, you may be eligible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with glioblastoma that does not have an IDH mutation.
- You completed radiation and temozolomide chemotherapy and your tumor did not get worse.
- You are not on high doses of steroids (more than 4 mg of dexamethasone per day).
- You are willing to avoid certain medications for 24 hours before and after the study drug.
- You have no other serious medical conditions or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new light-based treatment that is given alongside standard chemotherapy and radiation for people with a type of brain tumor called 'butterfly glioblastoma'. The goal is to see if adding this therapy can improve outcomes for patients with this challenging condition.
This study tests a light-activated therapy (radiodynamic therapy) using a special medicine to help treat a brain tumor that has come back after prior treatment. It may be offered after doctors decide you need further radiation for your recurrence.
This trial tests a new treatment called sonodynamic therapy that uses sound waves and a special drug to target brain tumors that have come back. It aims to see if this approach is safe and can shrink tumors in people who are eligible for surgery.
This trial tests whether adding the study drug azeliragon to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma. The study will also look at how the tumor responds to the added drug.
This study tests a new medicine (MT-125) combined with standard radiation and chemotherapy for people with newly diagnosed glioblastoma that has a specific gene change (MGMT methylated). The goal is to see if it is safe and tolerable, and to look for early signs it might help.
This trial tests combining an immunotherapy drug (adebrelimab) with the standard chemotherapy temozolomide, with or without hyperbaric oxygen treatment, for patients with newly diagnosed glioblastoma who have already completed standard radiation and chemotherapy. The goal is to see if this combination can improve outcomes.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.